This issue covers life sciences developments in the areas of intellectual property, regulatory, pricing and reimbursement, international trade, litigation, and competition that are of particular importance across Europe, Asia, and the United States. It also provides some of the latest information on Brexit.
Trendy Genes – Citing Surge in Cell and Gene Therapy IND Submissions, FDA Previews New Related Policies
Human cell and gene therapy research has advanced dramatically in recent years and opened the door to potential treatments for diseases once considered incurable.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) CMO Dr. Ralph Kern sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.
NEW YORK & SAN FRANCISCO & CARLSBAD, Calif.--(BUSINESS WIRE)--Biotech Showcase™, one of the most influential international biotechnology investor conferences in the world, concluded in San Francisco the second week of January and brought together more than 3,600 decision makers and biotech investors shaping the biopharmaceutical industry.
NEW YORK, SAN FRANCISCO, & CARLSBAD, Calif.--(BUSINESS WIRE)--Biotech Showcase™, one of the largest biotech investor conferences in the world, presents this year’s conference agenda which highlights six therapeutic areas that are garnering investment interest in 2019.
The last 20 years have witnessed a seismic change in the biotech industry - and the world. Not only has the rapid growth of science and technological advances changed what is possible in the business of biotechnology, but so too have business models and investment acumen. The entire space has experienced growth and maturity that newer entrants wouldn’t believe.
Those of us who have lived, as well as instigated, the evolution couldn’t be prouder of the biotech industry and the key players who have facilitated the changes that make the future possible. Today it is hard to believe that 20 years ago there was no such thing as transparency between pharma and biotech, and to be honest, it was because pharma was comfortable with their pipelines and didn’t want much to do with the untested and mostly unproven brave new world that was biotechnology.
The greatest ideas and innovations are those that fill a large gap in a field. And Biotech Showcase (BTS) was created for just such a purpose. There are hundreds, if not thousands, of biotech companies that are not ready for financing with the bulge bracket players – the largest and most recognized banks – like JPMorgan. Yet, they are ready to present their work and show investors how they have been hitting marks and building profiles. Thus, the creation of BTS. A place where small and mid-sized (and growing into larger) biotech companies can present, meet potential investors and partners, and know that the event organizers are on their side. And more importantly, fill that gap in the biotech space by helping those smaller companies get where they need to be.
I’ve been working with the biotechnology industry for the past 20 years. As an outside supporter of the industry, my goal has been to develop programs and services that facilitate the success of this industry and the companies that comprise it. With that as a constant, about three years ago I launched annual CEO gatherings in the US and Europe with the overarching theme of identifying and discussing success strategies for “The Purposeful (biotech) CEO.”
Dr. Fang Xie and Dr. Judy Jarecki-Black enlightened the participants about what it takes to obtain a patent in China and the different types of patents. During that same talk they explained the challenges of bringing new vaccines to China.
Sara Demy was recently interviewed by Janelle R. Anderson on the Human Proof of Concept podcast during Biotech Showcase. Janelle is currently a Managing Partner at CTI Life Sciences Fund. If [Biotech Showcase](https://ebdgroup.knect365.com/biotech-showcase/) is the farm team for JPM, then Sara Demy is the coach.
The 15th Annual Trans-Pacific Health Sciences Dialogue was a meeting for biopharmaceutical industry executives and business development executives who wanted to accelerate...
- 1 of 2
- next ›